Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. N-(8-(2-hydroxybenzoyl)amino)caprylate
2. N-(8-(2-hydroxybenzoyl)amino)caprylate Sodium
3. N-snac
4. Snac Sodium
5. Sodium N-(8-(2-hydroxybenzoyl)amino)caprylate
1. 203787-91-1
2. Snac
3. Sodium 8-(2-hydroxybenzamido)octanoate
4. E414
5. Salcaprozate Sodium [usan]
6. Sodium;8-[(2-hydroxybenzoyl)amino]octanoate
7. Octanoic Acid, 8-[(2-hydroxybenzoyl)amino]-, Monosodium Salt
8. Salcaprozate (sodium)
9. Sodium,8-[(2-hydroxybenzoyl)amino]octanoate
10. 1ytw0422yu
11. Sodium 8-[(2-hydroxybenzoyl)amino]octanoate
12. E-414
13. Sodium 8-((2-hydroxybenzoyl)amino)octanoate
14. Salcaprozate Sodium (usan)
15. Octanoic Acid, 8-((2-hydroxybenzoyl)amino)-, Monosodium Salt
16. Sodium Salcaprozate
17. Unii-1ytw0422yu
18. Salcaprozic Acid, Sodium Salt
19. E 414
20. Salcaprozate Sodium, 99%
21. Salcaprozic Acid Sodium Salt
22. Schembl825599
23. Chembl2107027
24. Dtxsid50174306
25. Amy24031
26. Ex-a3434
27. Mfcd00952954
28. Sodium8-(2-hydroxybenzamido)octanoate
29. Ac-31357
30. As-65676
31. P414
32. Hy-114299
33. Cs-0081977
34. Ft-0696582
35. D05787
36. I10998
37. A879665
38. Q27253228
39. Sodium 8-[(2-hydroxyphenyl)formamido]octanoate
40. Octanoic Acid, 8-[(2-hydroxybenzoyl)amino]-, Sodium Salt
41. Sodium,8-[(2-hydroxybenzoyl)amino]octanoate;sodium 8-(2-hydroxybenzamido)octanoate
| Molecular Weight | 301.31 g/mol |
|---|---|
| Molecular Formula | C15H20NNaO4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 9 |
| Exact Mass | 301.12900240 g/mol |
| Monoisotopic Mass | 301.12900240 g/mol |
| Topological Polar Surface Area | 89.5 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 312 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40217
Submission : 2024-07-22
Status : Active
Type : IV
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
Panvo Organics: Advancing quality APIs and formulations with Halal, Kosher, US FDA, and WHO-approved manufacturing excellence.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40217
Submission : 2024-07-22
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39618
Submission : 2024-10-10
Status : Active
Type : IV

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41533
Submission : 2025-03-15
Status : Active
Type : IV

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39651
Submission : 2024-03-14
Status : Active
Type : IV

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40767
Submission : 2024-11-11
Status : Active
Type : IV

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40072
Submission : 2024-06-18
Status : Active
Type : IV

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40329
Submission : 2026-02-24
Status : Active
Type : IV

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40177
Submission : 2024-07-16
Status : Active
Type : IV

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40147
Submission : 2024-06-27
Status : Active
Type : IV

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 76339-179
Start Marketing Date : 2022-11-04
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (24.999kg/24.999kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 76339-505
Start Marketing Date : 2023-11-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (24.999kg/24.999kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 73212-066
Start Marketing Date : 2023-10-01
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 42571-541
Start Marketing Date : 2025-06-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 71666-012
Start Marketing Date : 2021-03-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 85512-3037
Start Marketing Date : 2025-01-01
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 85203-000
Start Marketing Date : 2026-04-16
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
About the Company : Ami Lifesciences, established in 2006, is a rapidly growing API manufacturing company in India with strong capabilities in cardiovascular, anti-diabetic, CNS, and respiratory thera...
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and trusted manufacturer of specialty chemicals and ingredients, with seven world-class facilities meeting global safety and quality standards. Thro...
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
About the Company : Willow Birch Pharma, Inc. is a premier supplier of bulk APIs to North American Compounding Pharmacies, sourcing from FDA registered and GMP manufacturers. With licenses in all 50 s...
Panvo Organics: Advancing quality APIs and formulations with Halal, Kosher, US FDA, and WHO-approved manufacturing excellence.
About the Company : Panvo Organics Pvt. Ltd., established in 2006, is a WHO-GMP certified manufacturer of Active Pharmaceutical Ingredients, novel formulations, and sustainable agriculture inputs. The...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
LY3493269 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): LY3493269,Sodium Decanoate,Salcaprozate Sodium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LY3493269,Sodium Decanoate,Salcaprozate Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multiple-Dose Study of LY3493269 in Healthy Participants
Details : LY3493269 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 03, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
NNC0385-0434 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.
Lead Product(s): NNC0385-0434,Salcaprozate Sodium
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NNC0385-0434,Salcaprozate Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NNC0385-0434 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
NNC0385-0434 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atherosclerosis.
Lead Product(s): NNC0385-0434,Salcaprozate Sodium
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NNC0385-0434,Salcaprozate Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NNC0385-0434 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atherosclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 05, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
LY3493269 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): LY3493269,Salcaprozate Sodium
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LY3493269,Salcaprozate Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of LY3493269 in Healthy Participants
Details : LY3493269 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Lead Product(s): Furosemide,Rosuvastatin Calcium,Salcaprozate Sodium,Semaglutide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Furosemide,Rosuvastatin Calcium,Salcaprozate Sodium,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Furosemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Lead Product(s): Semaglutide,Salcaprozate Sodium,Thyroxine
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Semaglutide,Salcaprozate Sodium,Thyroxine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 30, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
SNAC is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Salcaprozate Sodium,Moxifloxacin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 22, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Salcaprozate Sodium,Moxifloxacin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNAC is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 22, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Lead Product(s): Semaglutide,Salcaprozate Sodium,Ethinyl Estradiol,Levonorgestrel
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 27, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Semaglutide,Salcaprozate Sodium,Ethinyl Estradiol,Levonorgestrel
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 27, 2016

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
11 Dec 2025
Reply
29 Sep 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
43
PharmaCompass offers a list of Salcaprozate Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Salcaprozate Sodium manufacturer or Salcaprozate Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Salcaprozate Sodium manufacturer or Salcaprozate Sodium supplier.
A Salcaprozate Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Salcaprozate Sodium, including repackagers and relabelers. The FDA regulates Salcaprozate Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Salcaprozate Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Salcaprozate Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Salcaprozate Sodium supplier is an individual or a company that provides Salcaprozate Sodium active pharmaceutical ingredient (API) or Salcaprozate Sodium finished formulations upon request. The Salcaprozate Sodium suppliers may include Salcaprozate Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Salcaprozate Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Salcaprozate Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Salcaprozate Sodium active pharmaceutical ingredient (API) in detail. Different forms of Salcaprozate Sodium DMFs exist exist since differing nations have different regulations, such as Salcaprozate Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Salcaprozate Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Salcaprozate Sodium USDMF includes data on Salcaprozate Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Salcaprozate Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Salcaprozate Sodium suppliers with USDMF on PharmaCompass.
A Salcaprozate Sodium written confirmation (Salcaprozate Sodium WC) is an official document issued by a regulatory agency to a Salcaprozate Sodium manufacturer, verifying that the manufacturing facility of a Salcaprozate Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Salcaprozate Sodium APIs or Salcaprozate Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Salcaprozate Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Salcaprozate Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Salcaprozate Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Salcaprozate Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Salcaprozate Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Salcaprozate Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Salcaprozate Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Salcaprozate Sodium suppliers with NDC on PharmaCompass.
Salcaprozate Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Salcaprozate Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Salcaprozate Sodium GMP manufacturer or Salcaprozate Sodium GMP API supplier for your needs.
A Salcaprozate Sodium CoA (Certificate of Analysis) is a formal document that attests to Salcaprozate Sodium's compliance with Salcaprozate Sodium specifications and serves as a tool for batch-level quality control.
Salcaprozate Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Salcaprozate Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Salcaprozate Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Salcaprozate Sodium EP), Salcaprozate Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Salcaprozate Sodium USP).